Cutaneous Clinical Trials

1 recruiting

Cutaneous Trials at a Glance

293 actively recruiting trials for cutaneous are listed on ClinicalTrialsFinder across 6 cities in 57 countries. The largest study group is Not Applicable with 86 trials, with the heaviest enrollment activity in New York, Boston, and Houston. Lead sponsors running cutaneous studies include National Cancer Institute (NCI), Mayo Clinic, and M.D. Anderson Cancer Center.

Treatments under study

About Cutaneous Clinical Trials

Looking for clinical trials for Cutaneous? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cutaneous trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cutaneous clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 293 trials

Recruiting
Phase 1Phase 2

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Melanoma+10 more
National Cancer Institute (NCI)16 enrolled26 locationsNCT05896839
Recruiting
Phase 2

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Head and Neck Squamous Cell Carcinoma+22 more
National Cancer Institute (NCI)150 enrolled221 locationsNCT05136196
Recruiting
Phase 3

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Eyelid Squamous Cell Carcinoma+17 more
National Cancer Institute (NCI)420 enrolled206 locationsNCT06568172
Recruiting

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

Chronic Lymphocytic Leukemia (CLL)Hairy Cell Leukemia (HCL)Non-Hodgkins Lymphoma (NHL)+2 more
National Cancer Institute (NCI)1,263 enrolled1 locationNCT01087333
Recruiting
Not Applicable

Hybrid Percutaneous Coronary Intervention Combining a Bioresorbable Scaffold With Drug-coated Balloons Versus a Conventional Drug-eluting Stent-based Strategy in Patients With Long and Diffuse Coronary Artery Disease

Coronary Artery DiseasePercutaneous Coronary Intervention (PCI)Diffuse Coronary Artery Disease
University Hospital, Geneva150 enrolled1 locationNCT06710210
Recruiting
Phase 3

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Metastatic Head and Neck Squamous Cell CarcinomaStage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Recurrent Head and Neck Squamous Cell Carcinoma+18 more
National Cancer Institute (NCI)158 enrolled176 locationsNCT06589804
Recruiting

Characterization of the Microbiome in Cutaneous T Cell Lymphoma

Cutaneous T Cell Lymphoma
Northwestern University300 enrolled1 locationNCT03932279
Recruiting
Not Applicable

ESP Block vs Control for Pain Control Following Percutaneous Nephrolithotomy

Nephrolithotomy, Percutaneous
University of Tennessee Medical Center128 enrolled1 locationNCT05024344
Recruiting

Natural History of Individuals With Immune System Problems That Lead to Fungal Infections

Invasive AspergillosisAPECEDChronic Mucocutaneous Candidiasis+1 more
National Institute of Allergy and Infectious Diseases (NIAID)1,200 enrolled1 locationNCT01386437
Recruiting
Not Applicable

Orbital Atherectomy vs Intravascular Lithotripsy for the Treatment of Calcified Coronary Nodules (ORBIT-SHOCK).

Chronic Coronary SyndromeCoronary Arterial Disease (CAD)Percutaneous Coronary Intervention (PCI)+6 more
Spanish Society of Cardiology50 enrolled6 locationsNCT06736665
Recruiting
Not Applicable

ELEVATE High-Risk PCI Pivotal Study

High-Risk Percutaneous Coronary Intervention (High-risk PCI)
Magenta Medical Ltd.290 enrolled29 locationsNCT07001332
Recruiting
Phase 3

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

Systemic Lupus Erythematosus (SLE)Cutaneous Lupus Erythematosus (CLE)
EMD Serono Research & Development Institute, Inc.202 enrolled3 locationsNCT07332481
Recruiting
Phase 2

Photopheresis in Early-stage Mycosis Fungoides

Mycosis FungoidesCutaneous T Cell Lymphoma
Columbia University74 enrolled1 locationNCT05680558
Recruiting
Phase 2

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Head and Neck Squamous Cell CarcinomaStage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8+38 more
NRG Oncology98 enrolled149 locationsNCT06532279
Recruiting
Phase 2Phase 3

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus Erythematosus
Biogen450 enrolled314 locationsNCT05531565
Recruiting
Phase 3

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

Cutaneous Lupus ErythematosusSystematic Lupus Erythematosus
EMD Serono Research & Development Institute, Inc.202 enrolled3 locationsNCT07355218
Recruiting
Phase 3

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

Cutaneous Squamous Cell Carcinoma (CSCC)
Regeneron Pharmaceuticals369 enrolled49 locationsNCT06585410
Recruiting
Phase 3

Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular With High Risk of Recurrence

Cutaneous Squamous Cell Carcinoma (CSCC)
Centre Leon Berard266 enrolled28 locationsNCT06692556
Recruiting

Effects of Spinal vs General Anesthesia on Systemic Inflammation in PCNL

Systemic InflammationAnesthesia TechniquesPercutaneous Nephrolithotomy
Elazıg Fethi Sekin Sehir Hastanesi90 enrolled1 locationNCT07326670
Recruiting
Not Applicable

Suture-Mediated Closure System Following Percutaneous Common Femoral Vein Procedures

Percutaneous Intervention Via Common Femoral Vein
Suzhou Hengruihongyuan Medical Technology Co. LTD136 enrolled1 locationNCT07554976